$11.20
32.70%
Nasdaq, Apr 21, 08:18 pm CET
ISIN
US30205M1018
Symbol
XCUR

Exicure Inc Stock price

$8.44
-4.55 35.03% 1M
+5.53 190.03% 6M
-5.23 38.26% YTD
+5.45 182.51% 1Y
-16.81 66.57% 3Y
-299.06 97.26% 5Y
-456.56 98.18% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
-3.11 26.93%
ISIN
US30205M1018
Symbol
XCUR
Sector
Industry

Key metrics

Market capitalization $53.32m
Enterprise Value $46.75m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 93.50
P/S ratio (TTM) P/S ratio 106.64
P/B ratio (TTM) P/B ratio 7.51
Revenue (TTM) Revenue $500.00k
EBIT (operating result TTM) EBIT $-4.95m
Free Cash Flow (TTM) Free Cash Flow $-2.91m
Cash position $12.51m
EPS (TTM) EPS $-2.59
Short interest 0.60%
Show more

Is Exicure Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Exicure Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Exicure Inc:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Exicure Inc:

Hold
100%

Financial data from Exicure Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.50 0.50
-
100%
- Direct Costs 0.82 0.82
41% 41%
164%
-0.32 -0.32
77% 77%
-64%
- Selling and Administrative Expenses 3.80 3.80
66% 66%
760%
- Research and Development Expense - -
-
-
-4.13 -4.13
67% 67%
-826%
- Depreciation and Amortization 0.82 0.82
41% 41%
164%
EBIT (Operating Income) EBIT -4.95 -4.95
65% 65%
-990%
Net Profit -9.70 -9.70
43% 43%
-1,940%

In millions USD.

Don't miss a Thing! We will send you all news about Exicure Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Exicure Inc Stock News

Neutral
Business Wire
7 days ago
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma.
Neutral
Business Wire
10 days ago
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML).
Neutral
Business Wire
about one month ago
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Reports Full Year 2024 Financial Results.
More Exicure Inc News

Company Profile

Exicure, Inc. is a clinical-stage biotechnology company, which engages in the discovery, research, and development of treatments based on spherical nucleic acid technology (SNA). It focuses on neurology, immuno-oncology, inflammatory diseases, and other genetic disorders. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL.

Head office United States
CEO Andy Yoo
Employees 7
Founded 2011
Website www.exicuretx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today